RMY Stock Chart & Stats
€26.00
€0.20(0.78%)
At close: 4:00 PM EDT
€26.00
€0.20(0.78%)
Day’s Range― - ―
52-Week Range€17.10 - €26.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.15B
Enterprise Value€20.25K
Total Cash (Recent Filing)€469.00M
Total Debt (Recent Filing)€17.53B
Price to Earnings (P/E)37.6
Beta0.65
Next Earnings
Aug 27, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.18
Shares Outstanding230,829,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-12.49
Price to Book (P/B)5.91
Price to Sales (P/S)1.67
P/FCF Ratio42.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.29Price Target Upside1.13% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)0.98
Revenue Forecast (FY)€11.79B
Bulls Say, Bears Say
Bulls Say
Australian Operations MomentumSustained Australia growth reflects durable demand in the private-pay market, improving theatre utilisation and higher case acuity. This regionally concentrated earnings engine supports predictable cash flow and margin expansion over the medium term, underpinning group profitability and reinvestment.
Improving Cash Flow And RefinancingStronger OCF and active refinancing materially reduce near-term refinancing and interest-rate risk, improving liquidity headroom. Durable cash-conversion gains and hedging lower funding volatility, enabling capex discipline, dividends and execution of strategic initiatives over the coming months.
Operational Transformation And Capacity ExpansionMultiyear transformation, capacity adds and targeted hospital initiatives are structural drivers of productivity and revenue per bed. Improved NPS, clinical-trials growth and digital efficiency can sustainably raise throughput and margins as new theatres scale and operating best-practices embed.
Bears Say
High Consolidated LeverageMaterial leverage and a sharp ROE decline constrain financial flexibility and increase vulnerability to rate or volume shocks. Elevated net debt limits capacity for growth M&A and increases refinancing needs, making earnings more sensitive to macro and operational setbacks over the medium term.
UK NHS Funding HeadwindsPersistent NHS funding uncertainty is a structural risk for UK volumes and pricing, reducing revenue visibility where the company serves public payors. Prolonged weak NHS activity can depress utilisation and margins in a material region, requiring sustained operational offsets or contractual fixes.
Elysium Underperformance And RestructuringA prolonged turnaround with site closures and lower occupancy signals structural demand and cost issues in mental-health operations. Persistent underutilisation and higher operating costs can weigh on group margins and cash conversion until occupancy recovers or the business is right-sized.
Ramsay Health Care News
RMY FAQ
What was Ramsay Health Care’s price range in the past 12 months?
Ramsay Health Care lowest stock price was €17.10 and its highest was €26.80 in the past 12 months.
What is Ramsay Health Care’s market cap?
Ramsay Health Care’s market cap is €6.15B.
When is Ramsay Health Care’s upcoming earnings report date?
Ramsay Health Care’s upcoming earnings report date is Aug 27, 2026 which is in 26 days.
How were Ramsay Health Care’s earnings last quarter?
Ramsay Health Care released its earnings results on Feb 25, 2026. The company reported €0.43 earnings per share for the quarter, beating the consensus estimate of €0.362 by €0.068.
Is Ramsay Health Care overvalued?
According to Wall Street analysts Ramsay Health Care’s price is currently Undervalued.
Does Ramsay Health Care pay dividends?
Ramsay Health Care does not currently pay dividends.
What is Ramsay Health Care’s EPS estimate?
Ramsay Health Care’s EPS estimate is 0.4.
How many shares outstanding does Ramsay Health Care have?
Ramsay Health Care has 230,829,800 shares outstanding.
What happened to Ramsay Health Care’s price movement after its last earnings report?
Ramsay Health Care reported an EPS of €0.43 in its last earnings report, beating expectations of €0.362. Following the earnings report the stock price went up 10.528%.
Which hedge fund is a major shareholder of Ramsay Health Care?
Currently, no hedge funds are holding shares in DE:RMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ramsay Health Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€26.29 (1.13% Upside)
€26.29 (1.13% Upside)
Blogger Sentiment
Bullish
DE:RMY Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.08%
12-Months-Change
Fundamentals
Return on Equity
2.19%
Trailing 12-Months
Asset Growth
13.13%
Trailing 12-Months
Company Description
Ramsay Health Care
Ramsay Health Care Limited is a prominent healthcare provider that manages and possesses hospitals. The company delivers medical services to both publicly funded and privately insured individuals. It maintains a substantial international presence, operating roughly 532 facilities across the Asia Pacific region, the United Kingdom, France, and the Nordic nations. Founded in 1964, its corporate headquarters are situated in Sydney, Australia.
RMY Stock 12 Month Forecast
Average Price Target
€26.29
▲(1.13% Upside)
Technical Analysis
Healius Limited
―
Regis Healthcare Ltd.
―
Sonic Healthcare Limited
―
Integral Diagnostics Ltd.
―
Australian Clinical Labs Ltd
―








